Abiraterone-induced rhabdomyolysis resulting in acute kidney injury: A case report and review of the literature
2017 ◽
Vol 24
(4)
◽
pp. 314-318
◽
Keyword(s):
Abiraterone, a CYP17 inhibitor, blocks androgen biosynthesis in multiple tissue types. In combination with prednisone, it is approved as a first-line treatment for metastatic castration-resistant prostate cancer. We present a case of rhabdomyolysis associated with abiraterone therapy resulting in acute on chronic kidney injury in a patient with metastatic castration-resistant prostate cancer. Strict monitoring should be employed in patients started on abiraterone who have additional risk factors for developing rhabdomyolysis.
2020 ◽
Vol 38
(15_suppl)
◽
pp. 5570-5570
2010 ◽
Vol 67
(4)
◽
pp. 927-933
◽
2011 ◽
Vol 29
(27)
◽
pp. 3686-3694
◽
2014 ◽
Vol 32
(4_suppl)
◽
pp. 23-23
◽